TY - JOUR
T1 - Verdins in photodynamic therapy of squamous cell carcinoma
AU - Hayden, Richard E.
AU - McLear, Patrick W.
AU - Morgan, Alan R.
AU - Bischoff, James K.
N1 - Funding Information:
Received September 7, 1989, from the Department of Otolaryngology, Washington University School of Medicine, St Louis, MO; and the Department of Chemistry, University of Toledo, Toledo, OH. Accepted for publication November 6, 1989. Presented at the 92nd annual meeting of the American Academy of Otolaryngology-Head and Neck Surgery in Washington, DC, September 1988. Supported in part by NIH grant no. 5T32NS07278-02. Address correspondence and reprint requests to Richard E. Hayden, MD, Department of Otolaryngology, Washington University School of Medicine, 4911 Barnes Hospital Plaza, St Louis, MO 63110. Q 1990 by W.B. Saunders Company. 0196-0709/90/1102-0008$500/O
PY - 1990
Y1 - 1990
N2 - Photodynamic therapy (PDT) is a relatively new treatment modality employing photoactive drugs in combination with light to destroy malignant tissue. Porphyrins (ie, hematoporphyrin derivative and dihematoporphyrin ether) have been the most thoroughly investigated photoactive drugs. The primary limitation of the use of porphyrins in PDT is the shallow depth of effective tumor kill. Each photoactive drug is activated maximally by light of a particular wavelength, and longer wavelengths are able to penetrate tissue to a greater depth. Hematoporphyrin derivative and its semipurified form, dihematoporphyrin ether, are activated by light at 630 nm, which penetrates tissue to a maximum of 8 mm. The search for more effective photosensitizers is under way. Verdins, photoactive compounds in the class of chlorins, have recently been synthesized with activating wavelengths near 700 nm. This longer activation wavelength should theoretically allow a greater depth of tumor kill. Verdins have been shown to be effective photosensitizers in a urothelial carcinoma model in rats. In this study, we investigated the effectiveness of these compounds on squamous cell carcinoma in the hamster cheek pouch model.
AB - Photodynamic therapy (PDT) is a relatively new treatment modality employing photoactive drugs in combination with light to destroy malignant tissue. Porphyrins (ie, hematoporphyrin derivative and dihematoporphyrin ether) have been the most thoroughly investigated photoactive drugs. The primary limitation of the use of porphyrins in PDT is the shallow depth of effective tumor kill. Each photoactive drug is activated maximally by light of a particular wavelength, and longer wavelengths are able to penetrate tissue to a greater depth. Hematoporphyrin derivative and its semipurified form, dihematoporphyrin ether, are activated by light at 630 nm, which penetrates tissue to a maximum of 8 mm. The search for more effective photosensitizers is under way. Verdins, photoactive compounds in the class of chlorins, have recently been synthesized with activating wavelengths near 700 nm. This longer activation wavelength should theoretically allow a greater depth of tumor kill. Verdins have been shown to be effective photosensitizers in a urothelial carcinoma model in rats. In this study, we investigated the effectiveness of these compounds on squamous cell carcinoma in the hamster cheek pouch model.
UR - http://www.scopus.com/inward/record.url?scp=0025348567&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025348567&partnerID=8YFLogxK
U2 - 10.1016/0196-0709(90)90008-J
DO - 10.1016/0196-0709(90)90008-J
M3 - Article
C2 - 2343995
AN - SCOPUS:0025348567
SN - 0196-0709
VL - 11
SP - 125
EP - 130
JO - American Journal of Otolaryngology--Head and Neck Medicine and Surgery
JF - American Journal of Otolaryngology--Head and Neck Medicine and Surgery
IS - 2
ER -